References
- Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA: Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999;103:47-54. https://doi.org/10.1172/JCI3756
- Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18. https://doi.org/10.1053/sonc.2002.34874
- Chavakis E, Riecke B, Lin J, Linn T, Bretzel RG, Preissner KT, Brownlee M, Hammes HP: Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia 2002;45:262-267. https://doi.org/10.1007/s00125-001-0727-z
- Eliceiri BP, Cheresh DA: Role of alpha v integrins during angiogenesis. Cancer J 2000;6:S245-249.
- Hynes RO, Bader BL, Hodivala-Dilke K: Integrins in vascular development. Braz J Med Biol Res 1999;32:501-510. https://doi.org/10.1590/S0100-879X1999000500002
- Guo WJ, Giancotti FG: Integrin signalling during tumour progression. Nat Rev Mol Cell Bio 2004;5:816-826. https://doi.org/10.1038/nrm1490
- Liu Z, Wang F, Chen X: Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res 2008;69:329-339. https://doi.org/10.1002/ddr.20265
- Millard M, Odde S, Neamati N: Integrin targeted therapeutics. Theranostics 2011;1:154-188. https://doi.org/10.7150/thno/v01p0154
- Niu G, Chen X: Why integrin as a primary target for imaging and therapy. Theranostics 2011;1:30-47. https://doi.org/10.7150/thno/v01p0030
- Ruoslahti E, Pierschbacher MD: New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-497. https://doi.org/10.1126/science.2821619
-
Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ et al: Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [
$^{18}F$ ]Galacto-RGD. PLoS Med 2005;2:e70. https://doi.org/10.1371/journal.pmed.0020070 - Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C et al: Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 2008;49:879-886. https://doi.org/10.2967/jnumed.107.049452
- Mirfeizi L, Walsh J, Kolb H, Campbell-Verduyn L, Dierckx RA, Feringa BL, Elsinga PH, de Groot T, Sannen I, Bormans G et al: Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin alphavbeta3 expression in vivo. Nucl Med Biol 2013;40:710-716. https://doi.org/10.1016/j.nucmedbio.2013.04.003
- Lee JW, Park JA, Lee YJ, Shin UC, Kim SW, Kim BI, Lim SM, An GI, Kim JY, Lee KC: New Glucocyclic RGD Dimers for Positron Emission Tomography Imaging of Tumor Integrin Receptors. Cancer Biother Radiopharm 2016;31:209-216. https://doi.org/10.1089/cbr.2016.2015
- Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979;6:371-388. https://doi.org/10.1002/ana.410060502
- Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL: Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840. https://doi.org/10.1097/00004647-199609000-00008
- Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153-158. https://doi.org/10.1006/nimg.1996.0066
-
Guo N, Lang L, Li W, Kiesewetter DO, Gao H, Niu G, Xie Q, Chen X: Quantitative analysis and comparison study of [
$^{18}F$ ]AlF-NOTA-PRGD2, [$^{18}F$ ]FPPRGD2 and [$^{68}Ga$ ]Ga-NOTA-PRGD2 using a reference tissue model. PLoS One 2012;7:e37506. https://doi.org/10.1371/journal.pone.0037506 -
Guo N, Lang L, Gao H, Niu G, Kiesewetter DO, Xie Q, Chen X: Quantitative analysis and parametric imaging of
$^{18}F$ -labeled monomeric and dimeric RGD peptides using compartment model. Mol Imaging Biol 2012;14:743-752. https://doi.org/10.1007/s11307-012-0541-7 - Liu S: Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009;20:2199-2213. https://doi.org/10.1021/bc900167c
-
Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, von Guggenberg E, Pichler BJ, Virgolini I, Decristoforo C et al: [
$^{68}Ga$ ]NODAGA-RGD for imaging alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2011;38:1303-1312. https://doi.org/10.1007/s00259-011-1778-0 -
Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M: Novel
$^{64}Cu$ - and$^{68}Ga$ -labeled RGD conjugates show improved PET imaging of alpha(nu) beta(3) integrin expression and facile radiosynthesis. J Nucl Med 2011;52:1276-1284. https://doi.org/10.2967/jnumed.111.087700